AK-1, a specific SIRT2 inhibitor, induces cell cycle arrest by downregulating Snail in HCT116 human colon carcinoma cells

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 637-645

  Cheon, Min Gyeong ^a   Kim, Wootae ^a   Choi, Minji ^a   Kim, Ja Eun ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

AK 1; Cell cycle; G1 arrest; SIRT2; Snail

Indexed keywords

AK 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEASOME; PROTEIN P53; SIRTUIN 2; SMALL INTERFERING RNA; SULFONAMIDE; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; SIRT2 PROTEIN, HUMAN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; CSN2 GENE; ENZYME ACTIVITY; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION REGULATION; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; NF KAPPAB GENE; PROTEIN DEGRADATION; PROTEIN FUNCTION; SNAIL GENE; TRANSCRIPTION REGULATION; WOUND HEALING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

GASTROPODA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIRTUIN 2; SULFONAMIDES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; WOUND HEALING;

EID: 84919459426     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.10.012     Document Type: Article

References (51)

1. Saunders L.R., Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007, 26:5489-5504.
2. Harting K., Knoll B. SIRT2-mediated protein deacetylation: an emerging key regulator in brain physiology and pathology. Eur. J. Cell Biol 2010, 89:262-269.
3. Cha Y.I., Kim H.S. Emerging role of sirtuins on tumorigenesis: possible link between aging and cancer. BMB Rep 2013, 46:429-438.
4. de Oliveira R.M., Sarkander J., Kazantsev A.G., Outeiro T.F. SIRT2 as a therapeutic target for age-related disorders. Front. Pharmacol 2012, 3:82.
5. Park S.H., Zhu Y., Ozden O., Kim H.S., Jiang H., Deng C.X., et al. SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle signaling, and carcinogenesis. Transl. Cancer Res 2012, 1:15-21.
6. Outeiro T.F., Kontopoulos E., Altmann S.M., Kufareva I., Strathearn K.E., Amore A.M., et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007, 317:516-519.
7. Luthi-Carter R., Taylor D.M., Pallos J., Lambert E., Amore A., Parker A., et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7927-7932.
8. Chopra V., Quinti L., Kim J., Vollor L., Narayanan K.L., Edgerly C., et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep 2012, 1492-1497.
9. Taylor D.M., Balabadra U., Xiang Z., Woodman B., Meade S., Amore A., et al. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem. Biol 2011, 6:540-546.
10. Spires-Jones T.L., Fox L.M., Rozkalne A., Pitstick R., Carlson G.A., Kazantsev A.G. Inhibition of sirtuin 2 with sulfobenzoic acid derivative AK1 is non-toxic and potentially neuroprotective in a mouse model of frontotemporal dementia. Front. Pharmacol 2012, 3:42.
11. Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X., et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 2011, 20:487-499.
12. Serrano L., Martinez-Redondo P., Marazuela-Duque A., Vazquez B.N., Dooley S.J., Voigt P., et al. The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation. Genes Dev 2013, 27:639-653.
13. Li Z., Xie Q.R., Chen Z., Lu S., Xia W. Regulation of SIRT2 levels for human non-small cell lung cancer therapy. Lung Cancer 2013, 82:9-15.
14. Li Y., Dai D., Lu Q., Fei M., Li M., Wu X. Sirt2 suppresses glioma cell growth through targeting NF-kappaB-miR-21 axis. Biochem. Biophys. Res. Commun 2013, 441:661-667.
15. Li Y., Matsumori H., Nakayama Y., Osaki M., Kojima H., Kurimasa A., et al. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells 2011, 16:34-45.
16. Zhang Y., Au Q., Zhang M., Barber J.R., Ng S.C., Zhang B. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem. Biophys. Res. Commun 2009, 386:729-733.
17. He X., Nie H., Hong Y., Sheng C., Xia W., Ying W. SIRT2 activity is required for the survival of C6 glioma cells. Biochem. Biophys. Res. Commun 2012, 417:468-472.
18. Sunami Y., Araki M., Hironaka Y., Morishita S., Kobayashi M., Liew E.L., et al. Inhibition of the NAD-dependent protein deacetylase SIRT2 induces granulocytic differentiation in human leukemia cells. PLoS ONE 2013, 8:e57633.
19. Dan L., Klimenkova O., Klimiankou M., Klusmann J.H., van den Heuvel-Eibrink M.M., Reinhardt D., et al. The role of Sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica 2012, 97:551-559.
20. Hoffmann G., Breitenbucher F., Schuler M., Ehrenhofer-Murray A.E. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J. Biol. Chem 2014, 289:5208-5216.
21. Liu P.Y., Xu N., Malyukova A., Scarlett C.J., Sun Y.T., Zhang X.D., et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ 2012, 503-514.
22. Yang M.H., Laurent G., Bause A.S., Spang R., German N., Haigis M.C., et al. HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Mol. Cancer Res 2013, 11:1072-1077.
23. Yang M.H., Nickerson S., Kim E.T., Liot C., Laurent G., Spang R., et al. Regulation of RAS oncogenicity by acetylation. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:10843-10848.
24. Chen J., Chan A.W., To K.F., Chen W., Zhang Z., Ren J., et al. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3beta/beta-catenin signaling. Hepatology 2013, 57:2287-2298.
25. Zuo Q., Wu W., Li X., Zhao L., Chen W. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin. Oncol. Rep 2012, 27:819-824.
26. Saxena M., Dykes S.S., Malyarchuk S., Wang A.E., Cardelli J.A., Pruitt K. The sirtuins promote Dishevelled-1 scaffolding of TIAM1, Rac activation and cell migration. Oncogene 2013, E-pub. 10.1038/onc.2013.549.
27. Hiratsuka M., Inoue T., Toda T., Kimura N., Shirayoshi Y., Kamitani H., et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem. Biophys. Res. Commun 2003, 309:558-566.
28. Inoue T., Hiratsuka M., Osaki M., Yamada H., Kishimoto I., Yamaguchi S., et al. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 2007, 26:945-957.
29. Lai C.C., Lin P.M., Lin S.F., Hsu C.H., Lin H.C., Hu M.L., et al. Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol 2013, 34:1847-1854.
30. Ong C.A., Shapiro J., Nason K.S., Davison J.M., Liu X., Ross-Innes C., et al. Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. J. Clin. Oncol 2013, 31:1576-1582.
31. Ouaissi M., Sielezneff I., Silvestre R., Sastre B., Bernard J.P., Lafontaine J.S., et al. High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann. Surg. Oncol 2008, 15:2318-2328.
32. Dan L., Klimenkova O., Klimiankou M., Klusman J.H., van den Heuvel-Eibrink M.M., Reinhardt D., et al. The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica 2012, 97:551-559.
33. Lennerz V., Fatho M., Gentilini C., Frye R.A., Lifke A., Ferel D., et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:16013-16018.
34. Zahm J.M., Kaplan H., Herard A.L., Doriot F., Pierrot D., Somelette P., et al. Cell migration and proliferation during the in vitro wound repair of the respiratory epithelium. Cell Motil. Cytoskeleton 1997, 37:33-43.
35. Bonezzi K., Belotti D., North B.J., Ghilardi C., Borsotti P., Resovi A., et al. Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia 2012, 14:846-854.
36. Nguyen P., Lee S., Lorang-Leins D., Trepel J., Smart D.K. SIRT2 interacts with beta-catenin to inhibit Wnt signaling output in response to radiation-induced stress. Mol. Cancer Res 2014, 12:1244-1253.
37. Barrallo-Gimeno A., Nieto M.A. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005, 132:3151-3161.
38. Zhou B.P., Deng J., Xia W., Xu J., Li Y.M., Gunduz M., et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol 2004, 6:931-940.
39. Wu Y., Deng J., Rychahou P.G., Qiu S., Evers B.M., Zhou B.P. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009, 15:416-428.
40. Brown K., Gerstberger S., Carlson L., Franzoso G., Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 1995, 267:1485-1488.
41. Wu Y., Zhou B.P. Snail: more than EMT. Cell Adh. Migr 2010, 4:199-203.
42. Takahashi E., Funato N., Higashihori N., Hata Y., Gridley T., Nakamura M. Snail regulates p21(WAF/CIP1) expression in cooperation with E2A and Twist. Biochem. Biophys. Res. Commun 2004, 325:1136-1144.
43. Li Y., Nie H., Wu D., Zhang J., Wei X., Ying W. Poly(ADP-ribose) polymerase mediates both cell death and ATP decreases in SIRT2 inhibitor AGK2-treated microglial BV2 cells. Neurosci. Lett 2013, 544:36-40.
44. Petrilli A., Bott M., Fernandez-Valle C. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis. Oncotarget 2013, 4:2354-2365.
45. Ramakrishnan G., Davaakhuu G., Kaplun L., Chung W.C., Rana A., Atfi A., et al. Sirt2 deacetylase is a novel AKT binding partner critical for AKT activation by insulin. J. Biol. Chem 2014, 289:6054-6066.
46. Si X., Chen W., Guo X., Chen L., Wang G., Xu Y., et al. Activation of GSK3beta by Sirt2 is required for early lineage commitment of mouse embryonic stem cell. PLoS ONE 2013, 8:e76699.
47. Rothgiesser K.M., Erener S., Waibel S., Luscher B., Hottiger M.O. SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J. Cell Sci 2010, 123:4251-4258.
48. Lee A.S., Jung Y.J., Kim D., Nguyen-Thanh T., Kang K.P., Lee S., et al. SIRT2 ameliorates lipopolysaccharide-induced inflammation in macrophages. Biochem. Biophys. Res. Commun 2014, 450:1363-1369.
49. Han Y., Jin Y.H., Kim Y.J., Kang B.Y., Choi H.J., Kim D.W., et al. Acetylation of Sirt2 by p300 attenuates its deacetylase activity. Biochem. Biophys. Res. Commun 2008, 375:576-580.
50. Peck B., Chen C.Y., Ho K.K., Di Fruscia P., Myatt S.S., Coombes R.C., et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol. Cancer Ther 2010, 9:844-855.
51. McCarthy A.R., Sachweh M.C., Higgins M., Campbell J., Drummond C.J., van Leeuwen I.M., et al. Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner. Mol. Cancer Ther 2013, 12:352-360.